Cases and resources in vascular techniques
This section provides a selection of cases and resources provided by experts in vascular techniques.
This PVI 2025 session reviews practical strategies for managing complex AAA, from improving F/BEVAR outcomes and avoiding technical pitfalls to designing successful repairs and choosing between open and endovascular treatment for TAAA. A concise overview of the key principles guiding safer, smarter aortic interventions.
Check out this PVI 2025 session on extreme CLTI: retrograde recanalisation shows high technical success, re-entry devices expand treatment options, and below-the-ankle interventions—though challenging—can still save the foot with careful patient selection.
By watching this session, you will learn the following: design endografts to adapt to anatomical challenges, create a dedicated workflow for aortic procedures to avoid technical failures, and have bailout options when facing technical challenges when performing complex aortic endografting.
By watching this session, you will learn the following: select the appropriate technique to repair arch pathologies, include percutaneous strategies to ascending and arch repairs, and implement an endovascular option for ascending aorta lesions.
By watching this session, you will learn the following: determine which patients require early endovascular repair, create a dedicated follow-up protocol for patients with type B dissections, and implement a comprehensive workflow to safely perform FBEVAR in chronic dissections.
This PVI 2025 late-breaking trials session delivers key updates in limb ischemia, spanning acute, chronic, and no-option CLTI. The presentations highlight the efficacy and safety of contemporary endovascular devices, clarify long-term outcomes of drug-coated and drug-eluting technologies, and provide real-world evidence supporting evolving revascularisation strategies across complex PAD populations.
Dr. Per Skoog reviews the SWEDEPAD I and II trials, the largest PAD studies evaluating drug-eluting devices. SWEDEPAD I focused on CLTI patients, SWEDEPAD II on claudicants. Both studies showed no improvement in patient-centered outcomes compared with non-coated devices. These findings highlight that drug-eluting devices did not provide added benefit, offering key insights for everyday PAD management.
The PVI 2025 session covers access strategies, lesion preparation, near-occlusion and restenosis management, TCAR in challenging patients, and carotid dissections. Practical insights and advanced techniques are shared to tailor interventions to each patient.
